IRIS Accounts Production v24.3.2.46 02074100 Board of Directors 1.1.24 31.12.24 31.12.24 false true false false true false Fair value model Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh020741002023-12-31020741002024-12-31020741002024-01-012024-12-31020741002022-12-31020741002023-01-012023-12-31020741002023-12-3102074100ns15:EnglandWales2024-01-012024-12-3102074100ns14:PoundSterling2024-01-012024-12-3102074100ns10:Director12024-01-012024-12-3102074100ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3102074100ns10:SmallEntities2024-01-012024-12-3102074100ns10:AuditExempt-NoAccountantsReport2024-01-012024-12-3102074100ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3102074100ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3102074100ns10:FullAccounts2024-01-012024-12-3102074100ns10:OrdinaryShareClass12024-01-012024-12-3102074100ns10:Director22024-01-012024-12-3102074100ns10:CompanySecretary12024-01-012024-12-3102074100ns10:RegisteredOffice2024-01-012024-12-3102074100ns5:CurrentFinancialInstruments2024-12-3102074100ns5:CurrentFinancialInstruments2023-12-3102074100ns5:Non-currentFinancialInstruments2024-12-3102074100ns5:Non-currentFinancialInstruments2023-12-3102074100ns5:ShareCapital2024-12-3102074100ns5:ShareCapital2023-12-3102074100ns5:CapitalRedemptionReserve2024-12-3102074100ns5:CapitalRedemptionReserve2023-12-3102074100ns5:RetainedEarningsAccumulatedLosses2024-12-3102074100ns5:RetainedEarningsAccumulatedLosses2023-12-3102074100ns5:LandBuildings2023-12-3102074100ns5:FurnitureFittings2023-12-3102074100ns5:LandBuildings2024-01-012024-12-3102074100ns5:FurnitureFittings2024-01-012024-12-3102074100ns5:LandBuildings2024-12-3102074100ns5:FurnitureFittings2024-12-3102074100ns5:LandBuildings2023-12-3102074100ns5:FurnitureFittings2023-12-3102074100ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3102074100ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3102074100ns5:Secured2024-12-3102074100ns5:Secured2023-12-3102074100ns10:OrdinaryShareClass12024-12-31
REGISTERED NUMBER: 02074100 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 December 2024

for

RIO HEALTH PRODUCTS LTD

RIO HEALTH PRODUCTS LTD (REGISTERED NUMBER: 02074100)






Contents of the Financial Statements
for the year ended 31 December 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


RIO HEALTH PRODUCTS LTD

Company Information
for the year ended 31 December 2024







DIRECTORS: S M Smits
S M Smits





SECRETARY: S M Smits





REGISTERED OFFICE: Preston Park House
South Road
Brighton
East Sussex
BN1 6SB





REGISTERED NUMBER: 02074100 (England and Wales)





ACCOUNTANTS: Plus Accounting
Chartered Accountants
Preston Park House
South Road
Brighton
East Sussex
BN1 6SB

RIO HEALTH PRODUCTS LTD (REGISTERED NUMBER: 02074100)

Balance Sheet
31 December 2024

2024 2023
Notes £ £
FIXED ASSETS
Tangible assets 4 - 499,723
Investment property 5 494,368 -
494,368 499,723

CURRENT ASSETS
Stocks 53,864 55,608
Debtors 6 9,416 42,624
Cash at bank and in hand 67,410 34,322
130,690 132,554
CREDITORS
Amounts falling due within one year 7 (410,334 ) (312,559 )
NET CURRENT LIABILITIES (279,644 ) (180,005 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

214,724

319,718

CREDITORS
Amounts falling due after more than one
year

8

(172,984

)

(197,489

)
NET ASSETS 41,740 122,229

CAPITAL AND RESERVES
Called up share capital 10 60 60
Capital redemption reserve 40 40
Retained earnings 41,640 122,129
SHAREHOLDERS' FUNDS 41,740 122,229

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

RIO HEALTH PRODUCTS LTD (REGISTERED NUMBER: 02074100)

Balance Sheet - continued
31 December 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 7 April 2025 and were signed on its behalf by:





S M Smits - Director


RIO HEALTH PRODUCTS LTD (REGISTERED NUMBER: 02074100)

Notes to the Financial Statements
for the year ended 31 December 2024

1. STATUTORY INFORMATION

Rio Health Products Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Revenue comprises the amount receivable from customers for the sale of health products and associated items exclusive of VAT. Revenue is recognised at point of sale.

Tangible fixed assets
Tangible fixed assets are stated at cost (or deemed cost) less accumulated depreciation and accumulated impairment losses. Cost includes costs directly attributable to making the asset capable of operating as intended by management.

Depreciation is provided at the following annual rates in order to write off each asset over its useful life or, if held under a finance lease, over the lease term, whichever is the shorter. The effect of not providing for depreciation on short leasehold and improvements to property is not material to the financial statements.

Leasehold property - Over term of lease
Fixtures and fittings -20% reducing balance
Freehold property -No depreciation

Impairment policy
At each balance sheet date, the company reviews the carrying amount of its assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of an asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


RIO HEALTH PRODUCTS LTD (REGISTERED NUMBER: 02074100)

Notes to the Financial Statements - continued
for the year ended 31 December 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension plan for its employees. A defined contribution pension plan is a pension plan under which the company pays contributions into a separate entity. Once the contributions have been paid, the company has no further obligations.

The contributions are recognised as an expense in the income statement when they fall due. Amounts owed but not paid are shown in accruals as a liability in the Statement of financial position. The assets of the plan are held separately from the Company in independently administered funds.

Financial instruments
Financial assets, liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 4 ) .

RIO HEALTH PRODUCTS LTD (REGISTERED NUMBER: 02074100)

Notes to the Financial Statements - continued
for the year ended 31 December 2024

4. TANGIBLE FIXED ASSETS
Fixtures
Freehold and
property fittings Totals
£ £ £
COST
At 1 January 2024 494,368 127,624 621,992
Reclassification/transfer (494,368 ) - (494,368 )
At 31 December 2024 - 127,624 127,624
DEPRECIATION
At 1 January 2024 - 122,269 122,269
Charge for year - 1,071 1,071
Impairments - 4,284 4,284
At 31 December 2024 - 127,624 127,624
NET BOOK VALUE
At 31 December 2024 - - -
At 31 December 2023 494,368 5,355 499,723

5. INVESTMENT PROPERTY
Total
£
FAIR VALUE
Additions 494,368
At 31 December 2024 494,368
NET BOOK VALUE
At 31 December 2024 494,368

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£ £
Trade debtors 7,410 42,624
Other debtors 2,006 -
9,416 42,624

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£ £
Bank loans and overdrafts 16,944 16,484
Trade creditors 139,242 278,432
Amounts owed to group undertakings 252,460 -
Taxation and social security - 10,058
Other creditors 1,688 7,585
410,334 312,559

RIO HEALTH PRODUCTS LTD (REGISTERED NUMBER: 02074100)

Notes to the Financial Statements - continued
for the year ended 31 December 2024

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2024 2023
£ £
Bank loans 172,984 197,489

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 100,357 126,830

9. SECURED DEBTS

The following secured debts are included within creditors:

2024 2023
£ £
Bank loans 189,928 213,973

The loan is secured by a charge over the freehold property.

10. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £ £
60 Ordinary £1 60 60

11. ULTIMATE CONTROLLING PARTY

The company is controlled by its parent, TS Health Holding BV, a company incorporated in Holland.